OncoBact™: Oncolytic Bacteria Platform with Precision Targeting

Online Inquiry

Name *

Email *

Phone *

Services Interested *

Project Description

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.

One-stop Oncolytic Bacterial Therapy Development Platform

In the field of cancer therapy, Alfa Cytology offers one-stop oncolytic bacterial therapy development platform, providing a comprehensive solution for your oncolytic bacterial therapy development. Our platform covers full-process services from bacterial strain screening to efficacy evaluation. Under the leadership of OncoBact™, we are committed to enhancing therapeutic effects and offering innovative and comprehensive solutions to tackle complex cancer challenges. Whether you are seeking a breakthrough in monotherapy or exploring the potential of combination therapy, our platform can meet your needs.

Introduction to Oncolytic Bacteria Therapy

Oncolytic bacterial therapy is an emerging cancer treatment approach that selectively infects cancer cells, releases anti-tumor factors, or activates the immune system to achieve therapeutic effects. In recent years, it has gradually become a research hotspot in the field of tumor therapy due to its unique targeting and immune activation capabilities.

As an innovative approach in cancer treatment, oncolytic bacterial therapy demonstrates distinct advantages compared to conventional therapies:

Tumor Selectivity: Oncolytic bacteria selectively infect and colonize malignant cells while sparing healthy tissues, leveraging unique tumor microenvironment conditions (e.g., hypoxia, immunosuppression) for targeted action.
Immune Activation: Through tumor cell lysis, these bacteria release tumor-associated antigens and damage-associated molecular patterns (DAMPs), triggering dendritic cell maturation and cytotoxic T-cell responses, thereby amplifying systemic antitumor immunity.
Synergistic Therapeutic Effects: Preclinical studies confirm enhanced efficacy when combined with radiotherapy or chemotherapy, attributed to bacterial-induced tumor vascular normalization and microenvironment remodeling.

Fig. 1 Genetically engineered oncolytic bacteria as drug delivery systems for targeted cancer theranostics. (Chen, Y., et al., 2021)

Development of Oncolytic Bacteria Therapy

Name	Company	Bacteria Strain	Indication	Phase
ADXS11-001	Advaxis	Listeria monocytogenes	Cervical Cancer	Phase III
ADXS31-164	Advaxis	Listeria monocytogenes	HER2⁺ Solid Tumors	Phase II
ADXS31-162	Advaxis	Listeria monocytogenes	Prostate Cancer	Phase II
ADX-503	Advaxis	Listeria monocytogenes	Non-Small Cell Lung Cancer	Phase II
ADX-504	Advaxis	Listeria monocytogenes	Prostate Cancer	Phase I
VXM01	Vaximm	Salmonella Typhimurium Ty21a	Glioblastoma	Phase II
mp105	Lingsheng Biotech	Engineered E. coli	Solid Tumors	Phase I
SGN1	Huajin Pharma	Salmonella Typhimurium	Solid Tumors	Phase I
Saltikva	Salspera LLC	Salmonella Typhimurium	Pancreatic Cancer	Phase I
BVD-550	BicMed Valley	Clostridium novyi	Solid Tumors	Phase I
SYNB1891	Synlogic	E. coli Nissle 1917	Solid Tumors	Phase I
YB1 ver3.0	Vivite Biotech	Salmonella Typhimurium	Solid Tumors	IND

Disclaimer: Alfa Cytology focuses on providing preclinical research service. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.

Our Services

Select for Alfa Cytology's one-stop oncolytic bacterial therapy development platform and embark on a hassle-free and efficient R&D journey. We offer a full-spectrum service, from bacterial strain screening and genetic engineering to preclinical trial design and execution. By integrating industry resources and assembling top-notch professional teams, we're dedicated to propelling your oncolytic bacterial therapy projects forward.

Workflow of Oncolytic Bacteria Therapy Development

Bacterial Strain Screening

Providing a variety of candidate strain libraries (such as Salmonella, Listeria, etc.) and screen out the optimal strains based on your target tumor type.
Providing toxicity assessment and infection tests to ensure the safety and effectiveness of the strains.

Genetic Engineering in Bacteria

Designing genetic engineering schemes for oncolytic bacteria, including toxin gene insertion, immune activation factor expression, tumor-targeting molecule modification, etc.
Providing a variety of expression vectors and promoter libraries to support personalized modification needs.

In Vitro Functional Validation

Testing the infectivity, toxin release ability, immune activation effect, etc., of oncolytic bacteria in vitro environments.
Providing a variety of cell models (such as cancer cell lines, immune cell co-culture models).

In Vivo Efficacy Evaluation

Evaluating the anti-tumor effects, safety, and immune activation ability of oncolytic bacteria in animal models.
Providing a variety of tumor models (such as subcutaneous tumor models, orthotopic tumor models)

Why Choose One-stop Development Platform?

Fast
Delivery

Customized
Services

Technical
Support

Data
Transparency

Our platform provides full-process services from strain screening to efficacy evaluation, helping you:

Save Time and Resources: One-stop services avoid the cumbersome process of multi-institutional collaboration.
Reduce Development Risks: Professional teams ensure that every step meets scientific standards.
Accelerate Technology Transfer: Efficient support for the transfer from laboratory to applications.

At Alfa Cytology, we are committed to helping customers develop safe and effective oncolytic bacterial therapies and promoting innovation and breakthroughs in cancer treatment. We provide state-of-the-art solutions to solve core issues in the development of cancer therapy. For more on our one-stop solution, please contact us.

Reference

Chen, Y., et al. Genetically engineered oncolytic bacteria as drug delivery systems for targeted cancer theranostics. Acta biomaterialia. 2021, 124: 72-87.

For research use only.